PREVIEW: Johnson & Johnson Q1 rev seen rising, EPS estimated to fall

Shares in pharma and medical device company Johnson & Johnson JNJ.N down 0.6% on Monday with Q1 financial report due before market open on Tuesday

Analysts are estimating adj EPS of $2.66 vs $2.77 in Q1 2025 on rev of $23.63 bln vs $21.89 bln in year-ago quarter, according to LSEG data

In the last 8 quarters JNJ's EPS beat every time while rev met or beat 7 times

In January JNJ had forecast 2026 sales, profit ahead of Wall Street estimates, even with expected impact of drug pricing deal with the Trump administration and ~$500 million in tariffs on medical devices. In mid-March a judge threw out a jury’s award of $950 million in punitive damages against Johnson & Johnson related to its talc products.

JNJ last traded around $236.96 vs median PT of $244.50, up from $240 a month ago, as per LSEG, which shows 28 analyst ratings: 5 'strong buy,' 12 'buy' and 11 'hold'

YTD shares in JNJ up ~14% vs ~5% drop in S&P 500 healthcare sector .SPXHC, and a 0.1% dip for the Dow Industrials .DJI

JNJ options imply a 3.5% swing for the shares, in either direction, by Friday; that's higher than the stock's avg move, on the day of results, of 2.0%, over the last eight qtrs, according to Trade Alert